By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Viralytics Ltd 

66 Hunter Street, Suite 305, Level 3

  Sydney  2000  Australia
Phone: 61-2-8889-3671 Fax: 61-2-8068-6038



Company News
Viralytics Ltd (VLA.AX) To Present Final Clinical Data From CALM Trial At ASCO Annual Meeting 2015 5/13/2015 11:51:07 AM
Viralytics Ltd (VLA.AX) Update On CALM And STORM Clinical Trials At AACR Annual Meeting 4/22/2015 8:34:40 AM
Viralytics Ltd (VLA.AX) Receives UK Approval To Commence Clinical Trial Of CAVATAK In Bladder Cancer 11/14/2014 8:48:32 AM
Viralytics Ltd (VLA.AX) Release: Updated Positive Data From Phase 2 Trial Of CAVATAK In Late-Stage Melanoma 9/29/2014 10:13:00 AM
Viralytics Ltd (VLA.AX) Release: Positive Interim Phase 2 Trial Results For CAVATAKā„¢, Novel Cancer Immunotherapy 4/8/2014 4:20:05 PM
Viralytics Ltd (VLA.AX) Completes $27 Million Fund Raising 3/13/2014 8:59:47 AM
Viralytics Ltd (VLA.AX) To Present At Two US Institutional Investor Forums 3/7/2014 6:34:43 AM
Viralytics Ltd (VLA.AX) Seeks $27 Million To Fund Cancer Trials 1/30/2014 6:43:23 AM
Viralytics Ltd (VLA.AX) Release: Target Enrollment Achieved In CAVATAK™ USA Phase 2 Melanoma Trial With Excellent Interim Results 1/8/2014 10:12:23 AM
Viralytics Ltd (VLA.AX) Meets Primary Endpoint in CAVATAK Phase 2 Melanoma Trial 9/18/2013 6:35:48 AM